Agents, uses and methods for the treatment of synucleinopathy
US-2018194833-A1 · Jul 12, 2018 · US
Antibodies for the treatment of synucleinopathy
US10358482B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10358482-B2 |
| Application number | US-201715812251-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2017 |
| Priority date | Jul 13, 2015 |
| Publication date | Jul 23, 2019 |
| Grant date | Jul 23, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A monoclonal antibody which specifically binds to human alpha-synuclein and comprises: (a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:1; (b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO:2; (c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO:3; (d) a Light Chain CDR1 comprising the amino acid sequence of SEQ ID NO:4; (e) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO:5; and (f) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO:6. 2. The antibody of claim 1 , which is a single chain Fv, a disulphide-bonded Fv, an Fab fragment, a Fab′ fragment, or a F(ab) 2 fragment. 3. The antibody of claim 1 , wherein the antibody is a human antibody. 4. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8. 5. A pharmaceutical composition comprising the antibody of claim 1 , and a pharmaceutical acceptable carrier. 6. The antibody of claim 1 , which further comprises a detectable label. 7. The antibody of claim 6 , wherein the detectable label is a fluorescent label, a chemiluminescent label, a paramagnetic label, a radioisotopic label or an enzyme label. 8. A pharmaceutical composition comprising the antibody of claim 6 , and a pharmaceutically acceptable carrier. 9. The antibody of claim 1 , wherein the antibody binds an epitope within amino acid residues 112-117 (SEQ ID NO:9) of human alpha-synuclein (SEQ ID NO:10).
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
for peripheral neuropathies · CPC title
Drugs for disorders of the nervous system · CPC title
from primates, e.g. man · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10358482B2 cover?
- The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system …
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).